“Meeting the needs of our patients and customers by now offering two nasal naloxone products at different strengths – NARCAN ® Nasal Spray 4 mg and KLOXXADO ® Nasal Spray 8 mg – allows Emergent to do ...

Alongside over-the-counter NARCAN ® Nasal Spray 4 mg, prescription KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose ...

Alongside over-the-counter NARCAN ® Nasal Spray 4 mg, prescription KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg will expand Emergent's ability to distribute multiple life-saving opioid overdose ...

"Meeting the needs of our patients and customers by now offering two nasal naloxone products at different strengths - NARCAN ® Nasal Spray 4 mg and KLOXXADO ® Nasal Spray 8 mg - allows Emergent to do ...

GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose emergency ...

“Meeting the needs of our patients and customers by now offering two nasal naloxone products at different strengths – NARCAN® Nasal Spray 4 mg and KLOXXADO® Nasal Spray 8 mg – allows ...

Under the terms of the six-year agreement, Emergent will add KLOXXADO® Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.